Malignant peripheral nerve sheath tumors: Prognostic and diagnostic markers and therapeutic targets

Holly Meany; Brigitte C. Widemann; Nancy Ratner

doi:10.1007/978-3-642-32864-0_29

Malignant peripheral nerve sheath tumors: Prognostic and diagnostic markers and therapeutic targets

Holly Meany, Brigitte C. Widemann, Nancy Ratner

Research output: Chapter in Book/Report/Conference proceeding › Chapter

7 Scopus citations

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are the most common malignancy associated with NF1. At present, complete surgical removal is the only successful treatment for MPNST, and the outcome for unresectable, recurrent, or metastatic MPNST remains poor. Because 50 % of MPNSTs arise in individuals with NF1, and because the prognosis of NF1-associated MPNST appears to be worse than that of sporadic tumors, many studies of MPNST have used NF1 models and comparisons between sporadic and NF1 MPNST. Currently, molecular analyses and preclinical testing are beginning to aid in the identification of promising therapies to target these neoplasms. Knowledge of the epidemiology, clinical presentation, diagnosis, and prognostic factors for MPNST is anticipated to allow for earlier detection of, and more successful treatment for, MPNST.

Original language	English (US)
Title of host publication	Neurofibromatosis Type 1
Subtitle of host publication	Molecular and Cellular Biology
Publisher	Springer-Verlag Berlin Heidelberg
Pages	445-467
Number of pages	23
Volume	9783642328640
ISBN (Electronic)	9783642328640
ISBN (Print)	3642328636, 9783642328633
DOIs	https://doi.org/10.1007/978-3-642-32864-0_29
State	Published - Aug 1 2012
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)
Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1007/978-3-642-32864-0_29

Cite this

@inbook{74129d0918544d66aca817e2e3193a20,

title = "Malignant peripheral nerve sheath tumors: Prognostic and diagnostic markers and therapeutic targets",

abstract = "Malignant peripheral nerve sheath tumors (MPNSTs) are the most common malignancy associated with NF1. At present, complete surgical removal is the only successful treatment for MPNST, and the outcome for unresectable, recurrent, or metastatic MPNST remains poor. Because 50 % of MPNSTs arise in individuals with NF1, and because the prognosis of NF1-associated MPNST appears to be worse than that of sporadic tumors, many studies of MPNST have used NF1 models and comparisons between sporadic and NF1 MPNST. Currently, molecular analyses and preclinical testing are beginning to aid in the identification of promising therapies to target these neoplasms. Knowledge of the epidemiology, clinical presentation, diagnosis, and prognostic factors for MPNST is anticipated to allow for earlier detection of, and more successful treatment for, MPNST.",

author = "Holly Meany and Widemann, {Brigitte C.} and Nancy Ratner",

note = "Publisher Copyright: {\textcopyright} 2012 Springer-Verlag Berlin Heidelberg. All rights are reserved.",

year = "2012",

month = aug,

day = "1",

doi = "10.1007/978-3-642-32864-0_29",

language = "English (US)",

isbn = "3642328636",

volume = "9783642328640",

pages = "445--467",

booktitle = "Neurofibromatosis Type 1",

publisher = "Springer-Verlag Berlin Heidelberg",

}

TY - CHAP

T1 - Malignant peripheral nerve sheath tumors

T2 - Prognostic and diagnostic markers and therapeutic targets

AU - Meany, Holly

AU - Widemann, Brigitte C.

AU - Ratner, Nancy

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Malignant peripheral nerve sheath tumors (MPNSTs) are the most common malignancy associated with NF1. At present, complete surgical removal is the only successful treatment for MPNST, and the outcome for unresectable, recurrent, or metastatic MPNST remains poor. Because 50 % of MPNSTs arise in individuals with NF1, and because the prognosis of NF1-associated MPNST appears to be worse than that of sporadic tumors, many studies of MPNST have used NF1 models and comparisons between sporadic and NF1 MPNST. Currently, molecular analyses and preclinical testing are beginning to aid in the identification of promising therapies to target these neoplasms. Knowledge of the epidemiology, clinical presentation, diagnosis, and prognostic factors for MPNST is anticipated to allow for earlier detection of, and more successful treatment for, MPNST.

AB - Malignant peripheral nerve sheath tumors (MPNSTs) are the most common malignancy associated with NF1. At present, complete surgical removal is the only successful treatment for MPNST, and the outcome for unresectable, recurrent, or metastatic MPNST remains poor. Because 50 % of MPNSTs arise in individuals with NF1, and because the prognosis of NF1-associated MPNST appears to be worse than that of sporadic tumors, many studies of MPNST have used NF1 models and comparisons between sporadic and NF1 MPNST. Currently, molecular analyses and preclinical testing are beginning to aid in the identification of promising therapies to target these neoplasms. Knowledge of the epidemiology, clinical presentation, diagnosis, and prognostic factors for MPNST is anticipated to allow for earlier detection of, and more successful treatment for, MPNST.

UR - http://www.scopus.com/inward/record.url?scp=84885751067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885751067&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-32864-0_29

DO - 10.1007/978-3-642-32864-0_29

M3 - Chapter

AN - SCOPUS:84885751067

SN - 3642328636

SN - 9783642328633

VL - 9783642328640

SP - 445

EP - 467

BT - Neurofibromatosis Type 1

PB - Springer-Verlag Berlin Heidelberg

ER -

Malignant peripheral nerve sheath tumors: Prognostic and diagnostic markers and therapeutic targets

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this